Author:
Zou Ying S.,Fink Stephanie R.,Stockero Kimberly J.,Paternoster Sarah F.,Smoley Stephanie A.,Tun Han W.,Reeder Craig B.,Tefferi Ayalew,Dewald Gordon W.
Subject
Cancer Research,Oncology,Hematology
Reference18 articles.
1. Hematologic and cytogenetic (CTG) response to Lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study;List,2005
2. Efficacy of Lenalidomide in myelodysplastic syndromes;List;N Engl J Med,2005
3. For the MDS-003 study investigators. Hematologic and cytogenetic response to Lenalidomide in myelodysplastic syndrome with chromosome 5q deletion;List;N Engl J Med,2006
4. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies;Giagounidis;Clin Cancer Res,2006
5. Conventional Cytogenetics and Molecular Cytogenetics in Hematological Malignancies;Dewald,2005
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献